Shared Decisions, Living Donation

The contract between this chapter and the reader.

1. 1. Apply an individualized, goals-based approach to these decisions.
2. 2. Describe living-donor evaluation and its ethics.
3. 3. Conduct shared decision-making with a potential living donor.
4. 4. Advise on pregnancy after transplant.
5. 5. Manage the failing graft and the return to dialysis.
6. 6. Weigh re-transplant versus dialysis versus conservative care.
7. 7. Manage immunosuppression as the graft fails.
8. 8. Distinguish effective-care from preference-sensitive decisions.
9. 9. Conduct shared decision-making with natural-frequency framing and teach-back.

A sixty-second reading. Each bullet stands alone.

• These decisions are individualized and goals-based, made with the patient or donor, not by default.
• Living-donor evaluation confirms health and renal reserve and assesses the donor's small but real long-term risk.
• A living donor undergoes surgery for no medical benefit to themselves, so informed, uncoerced consent and a donor advocate are essential.
• Pre-emptive living donation gives the recipient the best outcome.
• Pregnancy is possible after transplant, ideally after one to two years with a stable graft and controlled blood pressure.
• Teratogenic immunosuppressants (mycophenolate, mTOR inhibitors) are switched to azathioprine before pregnancy.
• A failing graft prompts decisions about when to return to dialysis and whether to re-list.
• A pre-emptive re-transplant, before dialysis, gives the best outcome where feasible.
• As the graft fails, immunosuppression is balanced: tapering reduces infection and malignancy risk but risks sensitization and rejection of residual function.
• Effective-care decisions are settled by evidence; preference-sensitive ones by the patient's values.
• Whether to pursue re-transplant, dialysis, or conservative care as the graft fails is preference-sensitive.
• For a frail patient who is not a re-transplant candidate, conservative care is a legitimate path.
• Shared decision-making uses natural-frequency framing and teach-back, and is documented.

The medical core. An expert should agree these decisions are fully covered here.

Why it matters at the bedside

Transplantation is a cycle as much as a treatment: it often begins with a gift from a living donor and, when a graft eventually fails, asks whether to begin again. The hardest questions along the way — whether a healthy person should donate, whether to risk a pregnancy, what to do when the graft is failing — have no purely medical answer. They are decided by values, and the clinician's task is to make those choices real, informed, and the patient's own.

The individualized, goals-based approach

• As in the closing chapters of dialysis, these decisions are not defaulted but individualized: the right path depends on the patient's (or donor's) goals, circumstances, and values. The clinician's role is to lay out the real options and their consequences and to support a choice, not to impose one.

Living-donor evaluation and ethics

• Living donation is unique in medicine: a healthy person undergoes major surgery for no medical benefit to themselves, accepting a small but real long-term risk (a slight rise in lifetime CKD and ESKD risk, plus the surgical risk) for the benefit of another. Evaluation confirms the donor's health and renal reserve and quantifies that risk — but the ethics are as important as the medicine: the donation must be a free, informed, uncoerced choice.

Shared decision-making with the donor

• The donor's decision is theirs alone. Good practice provides an independent donor advocate, ensures the consent is informed and free of coercion (financial or familial), and guarantees the right to withdraw at any point, confidentially. The recipient's need does not override the donor's autonomy — and pre-emptive living donation, which gives the recipient the best outcome, must still rest on the donor's free choice.

Pregnancy after transplant

• Fertility often returns after transplantation, and pregnancy is possible and frequently successful — but planned. The guidance is to wait until the graft is stable (around one to two years) with good function and controlled blood pressure, and — crucially — to switch teratogenic immunosuppressants (mycophenolate, mTOR inhibitors) to azathioprine before conception (the maintenance chapter). The risks (pre-eclampsia, prematurity, graft effects) are managed by a multidisciplinary team, and whether and when to pursue pregnancy is the patient's values-led decision.

The failing graft: returning to dialysis

• Most grafts eventually fail (the chronic-dysfunction chapter), and the failing graft brings its own decisions: when to return to dialysis (planned, not as a crisis), whether to re-list, and — best of all where feasible — whether a pre-emptive re-transplant can be arranged before dialysis is needed. Planning ahead converts a crisis into a managed transition.

Re-transplant versus dialysis versus conservative care

• As the graft fails, the same three-way choice as at the start re-emerges: a re-transplant (pre-emptive if possible), a return to dialysis, or — for a frail patient who is not a re-transplant candidate — conservative care. This is preference-sensitive: it weighs the burden and risk of another transplant or dialysis against the patient's goals, and conservative care is a legitimate path, not a failure.

Managing immunosuppression as the graft fails

• A specific, delicate decision is what to do with immunosuppression as the graft fails and dialysis resumes. Tapering it reduces the cumulative infection, malignancy, and cardiovascular burden — but risks sensitizing the patient (compromising a future re-transplant) and rejecting any residual graft function. The balance is individualized: in a re-transplant candidate, avoiding over-sensitization weighs heavily; in one who is not, the harms of continued immunosuppression dominate.

Effective-care versus preference-sensitive

• The organising distinction holds here too. Effective-care decisions — the donor's medical suitability, the crossmatch, teratogen avoidance, immunosuppression targets, infection prophylaxis — are settled by evidence. Preference-sensitive decisions — whether to donate, whether and when to pursue pregnancy, re-transplant versus dialysis versus conservative care — are settled by values, and belong to the patient or donor.

The shared-decision process

• The process is the one that has run through all three volumes: choice talk (naming that a real choice exists), option talk (laying out options with natural-frequency numbers, not hazard ratios), and decision talk (eliciting values and deciding together), closed by teach-back and documented. It is how a healthy donor, a hopeful parent, or a patient facing a failing graft is helped to choose well — the human end of a deeply technical field.

Five fully-built tables.

Table A — The decisions in this chapter

Table B — Living donation

Table C — Pregnancy after transplant

Table D — The failing graft

Table E — Decision types

Visualise & Map

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Decisions where the right answer depends on the patient's or donor's values, not the evidence alone.

Effective-care decisions (not preference-sensitive)

• A donor's medical suitability and renal reserve — the evaluation dictates it.
• Requiring crossmatch compatibility — immunologic safety dictates it.
• Switching teratogenic immunosuppressants before pregnancy — evidence dictates it.
• Immunosuppression targets and infection prophylaxis — standard of care.

The conversation rehearsed as a skill. Numbers trace to Level 14.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Living-donor evaluation / consent note

• Medical suitability: health, renal reserve, long-term risk assessed ___.
• Donor advocate involved; consent informed and free of coercion: yes/no.
• Risks disclosed (surgical; small long-term CKD/ESKD): ___.
• Right to withdraw (confidential) understood: yes/no.
• Decision: the donor's own; pre-emptive donation considered ___.

Template 2 — Failing-graft goals-of-care / re-listing note

• Graft trajectory and timing of likely failure: ___.
• Re-transplant candidate? pre-emptive re-listing pursued ___.
• Return to dialysis planned (timing/modality): ___.
• Immunosuppression plan as graft fails (taper vs continue; sensitization): ___.
• If not a candidate: conservative care discussed; values recorded ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Metacognition anchored to this chapter's tensions. No answers provided.

1. 1. A living donor accepts real risk for someone else's benefit; how do you honour their altruism while making absolutely sure the choice is free?
2. 2. Family pressure on a potential donor can be subtle and well-meant; how do you detect coercion that no one intends as coercion?
3. 3. A failing graft offers the chance to start the cycle again or to stop; how do you help a patient who has already been through it once decide whether to do so again?
4. 4. Tapering immunosuppression to spare the patient can foreclose a future transplant; how do you weigh a present harm against a future possibility?
5. 5. Across dialysis and transplantation alike, the hardest decisions are the patient's to make; what does it take, in a deeply technical field, to truly hand the choice over?

Nine items, each anchored in this chapter. At least one per objective.